2023-08-18 13:35:12 ET
More on Evaxion Biotech ADS
- Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst
- Evaxion stock slumps ~10% despite developing AI tool for cancer therapy
- Evaxion stock surges ~25% on preclinical data for mRNA vaccine for cancer
- Evaxion rises ~15% as personalized cancer immunotherapy gets FDA fast track status
- Evaxion jumps 22% as FDA clears mid-stage trial for melanoma candidate
- Seeking Alpha’s Quant Rating on Evaxion Biotech ADS
- Earnings data for Evaxion Biotech ADS
For further details see:
Evaxion Biotech ADS GAAP EPS of -$0.21 misses by $0.01